MD2848F1 - Metoda de diagnostic diferential al hepatitei cronice virale C si hepatitei cronice C asociate cu infectie herpetica - Google Patents

Metoda de diagnostic diferential al hepatitei cronice virale C si hepatitei cronice C asociate cu infectie herpetica Download PDF

Info

Publication number
MD2848F1
MD2848F1 MDA20050049A MD20050049A MD2848F1 MD 2848 F1 MD2848 F1 MD 2848F1 MD A20050049 A MDA20050049 A MD A20050049A MD 20050049 A MD20050049 A MD 20050049A MD 2848 F1 MD2848 F1 MD 2848F1
Authority
MD
Moldova
Prior art keywords
viral hepatitis
lymphocytes
chronic viral
differential diagnosis
amount
Prior art date
Application number
MDA20050049A
Other languages
English (en)
Other versions
MD2848G2 (ro
Inventor
Vlada-Tatiana Dumbrava
Adela Turcanu
Iulianna Lupasco
Lucia Andries
Original Assignee
Vlada-Tatiana Dumbrava
Adela Turcanu
Iulianna Lupasco
Lucia Andries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlada-Tatiana Dumbrava, Adela Turcanu, Iulianna Lupasco, Lucia Andries filed Critical Vlada-Tatiana Dumbrava
Priority to MDA20050049A priority Critical patent/MD2848G2/ro
Publication of MD2848F1 publication Critical patent/MD2848F1/ro
Publication of MD2848G2 publication Critical patent/MD2848G2/ro

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Inventia se refera la medicina, si anume la hepatologie, si este destinata pentru monitorizarea tratamentului hepatitei virale C. Esenta metodei consta in aceea ca se determina subpopulatiile limfocitelor CD8 si CD4 si in cazul in care cantitatea limfocitelor CD8 constituie 17...20%, iar cantitatea limfocitelor CD4 - 40...44%, si indicele imunoregulator este mai mare sau egal cu 2,2, se stabileste diagnosticul hepatitei cronice virale C; iar in cazul in care cantitatea limfocitelor CD8 constituie 14...17%, iar cantitatea limfocitelor CD4 - 19...22%, si indicele imunoregulator este mai mic sau egal cu 1,3, se stabileste diagnosticul hepatitei virale C asociate cu virusul herpesului simplu.
MDA20050049A 2005-02-22 2005-02-22 Metodă de diagnostic diferenţial al hepatitei cronice virale C şi hepatitei cronice C asociate cu infecţie herpetică MD2848G2 (ro)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20050049A MD2848G2 (ro) 2005-02-22 2005-02-22 Metodă de diagnostic diferenţial al hepatitei cronice virale C şi hepatitei cronice C asociate cu infecţie herpetică

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20050049A MD2848G2 (ro) 2005-02-22 2005-02-22 Metodă de diagnostic diferenţial al hepatitei cronice virale C şi hepatitei cronice C asociate cu infecţie herpetică

Publications (2)

Publication Number Publication Date
MD2848F1 true MD2848F1 (ro) 2005-09-30
MD2848G2 MD2848G2 (ro) 2006-05-31

Family

ID=35057539

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20050049A MD2848G2 (ro) 2005-02-22 2005-02-22 Metodă de diagnostic diferenţial al hepatitei cronice virale C şi hepatitei cronice C asociate cu infecţie herpetică

Country Status (1)

Country Link
MD (1) MD2848G2 (ro)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD219Z (ro) * 2010-03-05 2011-01-31 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова Metodă de determinare a gradului de activitate a hepatitei cronice virale C
MD319Z (ro) * 2010-06-30 2011-08-31 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова Metodă de diagnosticare a hepatitei virale cronice D şi hepatitei mixte B+C
MD302Z (ro) * 2010-06-30 2011-07-31 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова Metodă de diagnosticare a hepatitelor virale cronice B şi C

Also Published As

Publication number Publication date
MD2848G2 (ro) 2006-05-31

Similar Documents

Publication Publication Date Title
Boeckh Complications, diagnosis, management, and prevention of CMV infections: current and future
Mertz Asymptomatic shedding of herpes simplex virus 1 and 2: implications for prevention of transmission
WO2007144720A3 (en) Ccr5 antagonist for enhancing immune reconstitution and treating opportunistic infection in hiv patients
Oh et al. Sustained type I interferon reinforces NK cell–mediated cancer immunosurveillance during chronic virus infection
EP2199391A4 (en) LATEN INFECTION TO HERPESVIRUS INVOLVED FACTOR AND USE THEREOF
Wicker et al. Vaccination of healthcare personnel: Spotlight on groups with underlying conditions
MD2848F1 (ro) Metoda de diagnostic diferential al hepatitei cronice virale C si hepatitei cronice C asociate cu infectie herpetica
Wang et al. Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia
White et al. Reciprocal transactivation between HIV-1 and other human viruses
Everson et al. 1177 RAPID AND SUSTAINED ACHIEVEMENT OF UNDETECTABLE HCV RNA DURING TREATMENT WITH RITONAVIR-BOOSTED DANOPREVIR/PEG-IFNa-2A/RBV IN HCV GENOTYPE 1 OR 4 PATIENTS: DAUPHINE WEEK 12 INTERIM ANALYSIS
Cromarty et al. Diminished HIV infection of target CD4+ T cells in a toll-like receptor 4 stimulated in vitro model
Foster et al. 57 ACTIVITY OF TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 2 AND 3 HEPATITIS-C PATIENTS: FINAL RESULTS OF STUDY C209
Gathe Jr et al. Long-term (120-week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study
Fried et al. IMPROVED SUSTAINED VIROLOGICAL RESPONSE (SVR) RATES WITH HIGHER, FIXED DOSES OF PEGINTERFERON ALFA-2A (40KD)(PEGASYS®) PLUS RIBAVIRIN (RBV)(COPEGUS®) IN PATIENTS WITH “DIFFICULT-TO-CURE” CHARACTERISTICS: 335
WO2008045017A3 (en) Sars and ebola inhibitors and use thereof, and methods for their discovery
FR2867982B1 (fr) Procede pour amplifier l'activite de vaccins therapeutiques
WO2006045616A3 (en) β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES
UA85377C2 (ru) Применение композиции, содержащей вирусоподобные частички hpv16 і hpv18 при приготовлении медикамента для профилактики инфекции и/или болезни, вызванной группой hpv онкогенных типов, способы индуцирования иммунной реакции, профилактики инфекции и/или болезни, профилактики в популяции субъектов инфекции вызванных одной или несколькими группами онкогенных типов hpv, вакцинная композиция, которая включает hpv16 і нр18
Bangham Human T-Lymphotropic Virus Type 1 (HTLV-1)–Associated Diseases
Graham Virus Interactions in HIV-1 and HSV-2 Co-Infection
Hollander STRINGS ATTACHED
Krastev et al. 58 RANDOMIZED, OPEN-LABEL, 12-WEEK COMPARISON OF CONTROLLED-RELEASE INTERFERON ALPHA2B+ RIBAVRIN VS. PEGYLATED-INTERFERON ALPHA2B+ RIBAVRIN IN TREATMENT-NAIVE GENOTYPE1 HEPATITIS C: 4 WEEK RESULTS FROM 480STUDY (PANEL A)
Martel-Laferriere et al. Cocaine/crack use is not associated with liver fibrosis progression in HIV-HCV co-infected patients: 1496
Yusuf et al. Prevalence of Human Pegivirus (HPgV)) Among HIV/AIDS Patients in Aminu Kano Teaching Hospital, Kano–Nigeria
Schuler et al. Herpesvirus Infections in the Immunocompromised Host

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees